<DOC>
	<DOCNO>NCT01080755</DOCNO>
	<brief_summary>This multicentric , longitudinal , observational study prospective follow-up Adult subject Growth Hormone Deficiency ( AGHD ) treat Saizen , every six month first year annually . At request health authority , sponsor arrange follow-up prescription treat subject within scope indication .</brief_summary>
	<brief_title>Metabolic Endocrinology Growth Hormone Adults</brief_title>
	<detailed_description>Adult growth hormone deficiency lead various effect . In subject , increase observe body fat mass often , increase blood lipid level , also lead increase risk death cardiovascular disease . Sometimes muscle mass reduce , thus affect physical performance , rectify exercise alone . And finally , decline bone density , increase risk fracture . In general , subject inadequate growth hormone secretion also show deficiency hormone secrete hypophysis ( pituitary gland ) . In spite adequate substitution possible related hormonal deficiency , subject also present psychomotor retardation , decrease tonus vitality , emotional lability , feel social isolation sexual problem . In France , marketing approval grant different recombinant growth hormone ( GH ) , include Saizen , treat AGHD subject . The indication Saizen adult follow : marked deficiency GH document dynamic test indicate somatotroph deficiency . The therapeutic benefit Saizen well good tolerance demonstrate marketing approval indication . It show treatment result significant improvement body composition cardiac function AGHD subject . After receive marketing approval Saizen basis indication adult , sponsor , set-up study France , request health authority , ensure follow-up prescription treat subject use Saizen post marketing approval . This request health authority also mention Treatment Information Form . OBJECTIVES - To ensure longitudinal follow-up GH-deficient adult subject treat Saizen France , description : 1. term condition prescription , 2. demographic clinical characteristic subject , 3. subject ' compliance 4. product tolerance . The data collect study concern demography , medical history , clinical biological characteristic subject , term condition prescription Saizen , tolerance subject ' compliance . The information gather hospital endocrinologist ( approximately 200 potential prescribing doctor France ) . The prescribing doctor shall care subject account treatment medical reason per his/her regular practice . The period inclusion subject cohort 3 year . The extension inclusion period discuss health authority third year inclusion . The follow-up period subject include 5 year . This follow-up carry regular interval 6 month first year ( 2 intermediate visit 6 month also available ) 12 month subsequent year .</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Adult subject treat Saizen , irrespective whether concern first time prescription renewal enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Adult Growth Hormone Deficiency</keyword>
	<keyword>Pituitary</keyword>
	<keyword>Saizen</keyword>
	<keyword>Somatropin</keyword>
	<keyword>Growth Hormone</keyword>
</DOC>